Form 4 for CRL Charles River Laboratories
Accepted 2026-06-02 16:35:17 ET · period of report 2026-05-29 · accession 0001100682-26-000093 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 16:35 | 2026-05-29 | CRL | Girshick Birgit | CEO | A - Grant | $180.71 | +9,961 | 41.0K | +32% | +$1.80M | |
| M | 2026-06-02 16:35 | 2026-05-30+ | CRL | Girshick Birgit | CEO | F - Tax | $180.71 | -1,582 | 39.4K | -4% | -$285.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-29 | A | A | 9,961 | $180.71 | 40,981 | D | — | — | (F1) Unvested restricted stock units annually ratably vest on: May 29, 2027; May 29, 2028; May 29, 2029; May 29, 2030. |
| 2 | Common | Common Stock | 2026-05-30 | F | D | 1,204 | $180.71 | 39,777 | D | — | — | |
| 3 | Common | Common Stock | 2026-05-31 | F | D | 378 | $180.71 | 39,399 | D | — | — |